News Lilly strikes again, buying Calytrix in $1.5bn deal Eli Lilly has added yet another name to its list of M&A deals this year after agreeing to buy blood disorder specialist Calytrix Bio for up to $1.5bn.
News Ipsen charts $1.75bn course for Kartos acquisition Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.
News Lilly's M&A team strikes again with $2.3bn Ajax takeover With the ink barely dry on a deal to buy Kelonia, Lilly has signed a $2.3bn deal to acquire Ajax Therapeutics and its JAK2 blood cancer therapy.
News Karyopharm eyes Xpovio filing in myelofibrosis on mixed data Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.
News Novartis sheds MorphoSys staff, sites after pelabresib delay Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.
News GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.